RxDoctor Payments Data

Hunganh Bui, MD

Family Medicine · Livingston, TXNPI 1073576401

Payments from drug & device makers

$11,938in general payments, 2019–2025

Across 733 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Bayer$786
  • Merck$747
  • Johnson & Johnson$525
  • plus $6K from 31 others

What the payments were for

  • Food & beverage$11,82799%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,938 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,884
Medicare patients
174
Services billed
1,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide159$265,569
FarxigaDapagliflozin Propanediol269$246,365
JardianceEmpagliflozin123$119,139
MounjaroTirzepatide89$112,786
KerendiaFinerenone111$105,356
EliquisApixaban98$87,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$71,963
Xigduo XrDapaglifloz Propaned/Metformin34$41,513
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$34,919
LinzessLinaclotide32$26,492
Xultophy 100-3.6Insulin Degludec/Liraglutide21$24,043
GlyxambiEmpagliflozin/Linagliptin22$22,522
Repatha SureclickEvolocumab29$20,752
TrulicityDulaglutide11$19,732
EntrestoSacubitril/Valsartan15$18,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$1,365$289,612180 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,588$259,984287 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$141$151,757158 claims
Lilly USA, LLCMounjaro, Trulicity$450$132,519100 claims
BayerKerendia$786$105,356111 claims
PfizerEliquis$501$87,20398 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,265$79,26597 claims
AbbVieLinzess, Synthroid$523$29,94086 claims
NovartisEntresto$507$18,78015 claims
Sumitomo Pharma America, Inc.Gemtesa$215$18,63515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Livingston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →